Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Valortim regulatory update

January 16, 2006 8:00 AM UTC

FDA granted Fast Track designation to Valortim to treat anthrax infection. The human monoclonal antibody (MAb) targeting anthrax protective antigen (PA) is in Phase I testing. ...